Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is a double-blind, randomized, study at a single clinical site investigating the effect of methylnaltrexone and naloxone versus placebo in healthy males who have received a short-acting opioid, remifentanil.
Condition or disease
Drug: NaloxoneDrug: IV Methylnaltrexone (MNTX)Drug: Placebo
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Accepts Healthy Volunteers:
Healthy males, 18 to 65 yrs with normal urinary function
Body weight less than 150 kg and Body Mass Index between 20-32.
History of drug or alcohol abuse
History of significant chronic illness (cardiovascular, gastrointestinal, pulmonary, neurologic, endocrine, renal, hepatic, etc.)
Subjects who received opioids for one week or longer in the last 2 months.